CompanyDrug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube
By
Fineline Cube
2 Min Read
Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
Summarize with AI

Bio‑Thera Solutions (SHA: 688177) submitted a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) for Velasitaximab injection (BAT5906), a recombinant humanized anti‑VEGF‑A165 monoclonal antibody, for the treatment of neovascular (wet) age‑related macular degeneration (nAMD).

Contents
- Advertisement -

Regulatory Milestone

ItemDetails
Submission Date19 Dec 2025
AgencyNMPA (China)
ProductVelasitaximab injection (BAT5906)
IndicationNeovascular (wet) AMD
InnovationIndependently developed IgG1‑type full‑length antibody (149 kDa)
MechanismBinds VEGF‑A165, blocking angiogenesis and endothelial cell proliferation

Drug Profile & Preclinical Data

AttributeBAT5906Competitive Landscape
Antibody TypeRecombinant humanized IgG1, 149 kDaSimilar to aflibercept (Eylea) and ranibizumab (Lucentis)
TargetVEGF‑A165 isoformPrecision targeting vs. pan‑VEGF‑A agents
MechanismBlocks VEGF‑receptor binding → inhibits angiogenesisStandard of care for nAMD
AdministrationIntravitreal injectionAligns with existing anti‑VEGF regimen
Preclinical EfficacyIn‑vitro models show potent inhibition of endothelial cell proliferation and neovascularizationValidated mechanism
DifferentiationFirst domestic‑developed VEGF‑A165‑selective antibodyPotential for cost advantage vs. imported biologics

Market Opportunity

MetricValueContext
China nAMD Prevalence~3‑5 million patients (2025)Growing at 5‑7% CAGR due to aging population
China Anti‑VEGF Market¥15‑20 billion (≈ US$2.1‑2.8 B)Dominated by Eylea, Lucentis, and off‑label Avastin
BAT5906 Peak Sales¥2‑3 billion (≈ US$280‑420 M) by 203010‑15% share if priced 30‑40% below imports
Competitive AdvantageDomestic manufacturing cost advantage; NRDL eligibilityFaster market access and reimbursement
Launch TimelinePotential 2027‑2028 approvalFiling under standard NDA pathway

Strategic Implications

  • For Bio‑Thera: NDA submission validates antibody platform beyond biosimilars; VEGF‑A165 selectivity positions for differentiated marketing; potential for global expansion if China data supports US/EU filings.
  • For Patients: Oral not available; injectable offers alternative to existing anti‑VEGF agents; cost‑effective option could improve access in tier‑2/3 cities.
  • For Market: First domestic VEGF‑A165 antibody challenges multinational dominance; NRDL negotiation likely in 2026; biosimilar pressure on Eylea/Lucentis creates pricing headroom.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding BAT5906’s regulatory review timeline, market penetration, and competitive positioning. Actual results may differ due to NMPA feedback, clinical risks, or competitive responses.-Fineline Info & Tech

688177_20251219_FSKUDownload
TAGGED:
Share This Article
Previous Article Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Next Article TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

You May also Like

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones
CompanyDeals

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones

CompanyMedical Device

Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME

Company

Aspen Pharmacare’s 2024 Fiscal Report Shows Mixed Results Amid China’s VBP Impact

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
CompanyDrug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Show More